Abstract:The pathobiology of MAFLD is such a big puzzle, and many of the metabolic and other health consequences of the disease are not yet fully elucidated. In their review on "Pathobiology of metabolic-associated fatty liver disease," Fouda and colleagues update the current evidence on the disease characteristics. The prevalence of MAFLD has reached epidemic proportions in children and young adults in the recent years, with figures reaching as high as 15% owing to the global obesity pandemic. Vespoli and colleagues in their review "MAFLD in childhood and adolescence" portray the latest updates and new emerging therapies for pediatric MAFLD. Gofton and colleagues update the association between metabolically unhealthy visceral adiposity and MAFLD in individuals with "normal body weight" in their review "Lean MAFLD." The pathobiological link between dyslipidemia and MAFLD is elaborated by Anwar and colleagues with the therapeutic algorithms. Ren and colleagues summarize evidence surrounding cardiovascular disease and MAFLD and analyze management strategies focusing on prevention of cardiovascular disease in MAFLD. Another important review by Kapoor and Kalra discusses the hot topic of diabetes and MAFLD and portrays the latest management strategies for both diseases. Barber and colleagues thoroughly review the gut-liver axis in the context of gut dysbiosis in MAFLD. Sarcopenia and MAFLD is the theme of the review by Bali and colleagues. This article emphasizes the importance of early identification of sarcopenia in patients with MAFLD and vice versa. Obstructive sleep apnea and MAFLD are often underdiagnosed and inadequately managed. Preshy and Brown in their review highlight the association between these common disorders to enhance the global awareness with updated evaluation and management strategies in their review. Mandato and colleagues review current literature on pregnancy and MAFLD and update the best clinical approach in their article. The interlink between polycystic ovary syndrome and MAFLD, their coexistence, diagnosis, and current management strategies are critically apprised by Vidal-Cevallos and colleagues in their review. Venkatesan and Haroon successively provide more important evidence for the clinical management of MAFLD with additional focus on minority groups and currently available therapies.

Molecular mechanisms of metabolic associated fatty liver disease (MAFLD): functional analysis of lipid metabolism pathways

Mechanisms Linking Metabolic-Associated Fatty Liver Disease (MAFLD) to Cardiovascular Disease

Lipid Disorders and Metabolic-Associated Fatty Liver Disease

Metabolic (dysfunction)-associated fatty liver disease in individuals of normal weight

The microbial metabolome in metabolic-associated fatty liver disease

Metabolic-Associated Fatty Liver Disease: A Disastrous Human Health Challenge

Underlying Mechanisms behind the Brain-Gut-Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

Metabolic-associated fatty liver disease: a selective review of pathogenesis, diagnostic approaches, and therapeutic strategies

Metabolic dysfunction associated fatty liver disease in healthy weight individuals

Mechanisms and therapeutic strategies for MAFLD targeting TLR4 signaling pathways

A Simpler Definition of MAFLD Precisely Predicts Incident Metabolic Diseases: a 7-Year Cohort Study

Detangling the interrelations between MAFLD, insulin resistance, and key hormones

MAFLD as part of systemic metabolic dysregulation

Therapeutics for Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)

Altered lipid metabolism and the development of metabolic-associated fatty liver disease

New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk

Metabolic dysfunction-associated fatty liver disease: current therapeutic strategies

Role of Insulin Resistance in MAFLD

Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease

Mitochondrial Dysfunction in Metabolic Dysfunction Fatty Liver Disease (MAFLD)

SGLT-2 inhibitors and GLP-1 receptor agonists in metabolic dysfunction-associated fatty liver disease